RxDoctor Payments Data

Allyson Leslie, APRN

Family · Carson City, NVNPI 1770297228

Payments from drug & device makers

$1,268in general payments, 2019–2025

Across 64 payments — averaging $19.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$207
  • Boehringer Ingelheim$157
  • Lilly USA, LLC$150
  • Pfizer$137
  • Merck$83
  • AstraZeneca$68
  • plus $467 from 12 others

What the payments were for

  • Food & beverage$1,26199%
  • Education$71%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,268 in reported general payments places this provider in the 75th percentile of 1,501 family providers in Nevada.

See all family providers in Nevada

Medicare billing

Part B allowed, 2024
$47,472
Medicare patients
199
Services billed
804

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide16$14,549
EliquisApixaban15$14,215
MounjaroTirzepatide11$11,822
Estradiol18$1,187
Atorvastatin Calcium50$784
Telmisartan14$711
Albuterol Sulfate HfaAlbuterol Sulfate31$688
Bupropion XlBupropion Hcl35$550
Levothyroxine Sodium63$503
ValacyclovirValacyclovir Hcl11$447
Montelukast Sodium14$384
Rosuvastatin Calcium26$296
Pantoprazole Sodium21$289
Nystatin15$282
Losartan Potassium38$282

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$207$14,54916 claims
PfizerEliquis$137$14,21515 claims
Lilly USA, LLCMounjaro$150$11,82211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,501 family providers in Nevada.

Other family in Carson City

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →